This emerging understanding suggests that a comprehensive investigation into Akt signaling and SREBPs, as well as a balanced view on these molecules, is highly necessary in the interpretation of drug effects on NASH [18]. Here, AKT1 is linked to metabolic dysfunction-associated steatohepatitis.